title: Muraglitazar and the FDA: what constitutes drug safety?
authors.affiliation: Section of Cardiology, Rush Medical College, Rush University Medical Center, Chicago, IL 60612, USA. pliebson@rush.edu
authors.forename: Philip R
authors.initials: PR
authors.lastname: Liebson
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D016208:Databases, Factual; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy; D017277:Drug Approval; D005998:Glycine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000592:standards; D006801:Humans; D010080:Oxazoles / Q000008:administration & dosage* / Q000009:adverse effects* / Q000592:standards; D047492:Peroxisome Proliferator-Activated Receptors / Q000009:adverse effects* / Q000819:agonists* / Q000592:standards; D016032:Randomized Controlled Trials as Topic; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001786:Blood Glucose; D010080:Oxazoles; D047492:Peroxisome Proliferator-Activated Receptors; D005998:Glycine; C500085:muraglitazar